Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q3 2025 Earnings Presentation
28 slides from Indivior Pharmaceuticals's earnings presentation, Oct 30, 2025
Slide 1: Q3 2025 Results
Q3 2025 Results October 30, 2025
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
Q3 2025 RESULTS | OCTOBER 30, 2025 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company’s financial gui
Slide 3: Joe Ciaffoni, Chief Executive Officer
Joe Ciaffoni Chief Executive Officer
Slide 4: Call Agenda
Q3 2025 RESULTS | OCTOBER 30, 2025 Call Agenda Execution Against the Indivior Action Agenda Joe Ciaffoni, CEO SUBLOCADE® Commercial Update Patrick Barry, CCO Q3 Performance & FY 2025 Guidance Ryan Preblick, CFO Conclusion Joe Ciaffoni, CEO Q&A All participants 4
Slide 5: Q3 2025 Business Highlights Raising Full-Year 2025 Financial Guidance
Q3 2025 RESULTS | OCTOBER 30, 2025 Q3 2025 Business Highlights Total SUBLOCADE Adjusted Net Revenue Net Revenue EBITDA1 +2% +15% $307m $314m +14% $219m $191m $120m $105m Q3'24 Q3'25 Q3'24 Q3'25 Q3'24 Q3'25 Raising Full-Year 2025 Financial Guidance 1Adjusted EBITDA is a Non-GAAP Financial Measure wit
Slide 6: Indivior Action Agenda
Q3 2025 RESULTS | OCTOBER 30, 2025 Indivior Action Agenda Phase I – Generate Momentum – Underway Phase III – Breakout (H2’26 – Beyond) • Leverage strengthened financial profile to acquire next growth drivers Phase II – Accelerate (Jan. ’26) • Accelerate U.S. SUBLOCADE net revenue • Generate immediat
Slide 7: Progress on Phase I of the Indivior Action Agenda
Q3 2025 RESULTS | OCTOBER 30, 2025 Progress on Phase I of the Indivior Action Agenda 1 2 3 Simplify the organization Determine actions and investments Grow SUBLOCADE in the U.S. and establish “go-forward” necessary to expand LAI penetration in operating model U.S. BMAT category to accelerate U.S. SU
Slide 8: Patrick Barry, Chief Commercial Officer
Patrick Barry Chief Commercial Officer
Slide 9: Q3 2025 U.S. SUBLOCADE Performance
Q3 2025 RESULTS | OCTOBER 30, 2025 Q3 2025 U.S. SUBLOCADE Performance Solid SUBLOCADE Dispense Growth1 TTM SUBLOCADE Patients2 +8% +5% YoY YoY +3% 174,674 QoQ 166,628 171,500 165,700 158,500 // Q3'24 Q3'25 Q3'24 Q2'25 Q3'25 Growing SUBLOCADE Prescriber Base3 Improving Prescriber Depth: +11% HCPs wit
Slide 10: Direct-To-Consumer Campaign: Move Forward in Recovery
Q3 2025 RESULTS | OCTOBER 30, 2025 Direct-To-Consumer Campaign: Move Forward in Recovery Launched on October 1 Omnichannel patient activation initiative including: • National television, digital, and social media • In-office and point of care materials • Newly designed patient website Committed to i
Slide 11: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 12: Q3 2025 Financial Highlights
Q3 2025 Results | OCTOBER 30, 2025 Q3 2025 Financial Highlights OPERATING RESULTS: KEY TAKEAWAYS: (vs. Q3 2024 unless otherwise indicated) $ mil Q3 2025 Q3 2024 Change Total Net Revenue (+2%) Strong SUBLOCADE net revenue growth more Net Revenue (NR): 314 307 2% than offsetting SUBOXONE Film Net Reve
Slide 13: Strong Balance Sheet with Significant Cash Flow Generation
Q3 2025 RESULTS | OCTOBER 30, 2025 Strong Balance Sheet with Significant Cash Flow Generation Cash & Cash Equivalents1 +$125m* ~$200m in net cash provided $473m by operations YTD $347m <1.0x adjusted leverage Dec 2024 Sep 2025 ratio2 1See discussion of obligations in Note 12 in SEC filed form 10-K o
Slide 14: Raising 2025 Financial Guidance: Reflecting Stronger Top-Line Growth
Q3 2025 RESULTS | OCTOBER 30, 2025 Raising 2025 Financial Guidance: Reflecting Stronger Top-Line Growth Previous Guidance Updated Guidance Change vs. (7/31/25) (10/30/25)1 20242 Total Net Revenue $1,030m - $1,080m $1,180m - $1,220m +1% SUBLOCADE Net Revenue $765m - $785m $825m - $845m +10% Non-GAAP
Slide 15: "Go-Forward" Operating Model Established
Q3 2025 RESULTS | OCTOBER 30, 2025 “Go-Forward” Operating Model Established Expect at least $150m in Non-GAAP Simplification Actions to Generate Savings Operating Expense Savings in 20261,2 Completed Pursuing LSE delisting U.S. domicile ~$60m ≥ $150m reduction reduction from high- end of guidance ra
Slide 16: Concluding Remarks
{32 iNDIviOR Concluding Remarks
Slide 17: Clear Focus on Executing Indivior Action Agenda and Delivering on Commitments
Q3 2025 RESULTS | OCTOBER 30, 2025 Clear Focus on Executing Indivior Action Agenda and Delivering on Commitments Executing on Phase I, Begin Phase II, Generate Momentum, Deliver on Raised 2025 Accelerate, on January of Indivior Action Financial Guidance 1, 2026 Agenda 17
Slide 18: YEARS OF
YEARS OF ae INDIVIOR
Slide 19: Appendix
al ( r7 iNDIVIOR Appendix
Slide 20: Key Ongoing Clinical Trials
Q3 2025 RESULTS | OCTOBER 30, 2025 Key Ongoing Clinical Trials Trial Population Patients Design Primary Endpoints Status Estimated Completion INDV-6001 Moderate to Evaluate PK, safety and 3-month long-acting severe Opioid Multiple dose tolerability of INDV-6001 Last Patient First Last Patient Last V
Slide 21: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP gross profit $ 230 $ 241 $ 702 $ 707 Adjustments within cost of sales Manufacturing transition 2 — 4 — Discontinuation of OPVEE
Slide 22: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP operating expenses $ 187 $ 206 $ 521 $ 715 Share-based compensation 6 6 21 18 Corporate initiative transition1 35 — 41 — Discon
Slide 23: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP general and administrative expenses $ 94 $ 87 $ 236 $ 250 Adjustments within G&A Share-based compensation 6 6 21 18 Corporate i
Slide 24: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP selling and marketing expenses $ 62 $ 55 $ 209 $ 188 Adjustments within S&M Corporate initiative transition1 6 — 6 — Discontinu
Slide 25: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP research and development expenses $ 33 $ 22 $ 76 $ 76 Adjustments within R&D Corporate initiative transition1 13 — 13 — Less: A
Slide 26: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP tax expense (benefit) $ (5) $ 8 $ 50 $ (4) Tax on non-GAAP adjustments (19) (20) (26) (66) Tax settlement1 (1) — 32 — Other tax
Slide 27: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP net income (loss) $ 42 $ 22 $ 108 $ (14) Adjustments in cost of sales 33 10 34 42 Adjustments in selling, general and 29 15 48
Slide 28: Financial Reconciliations
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Net income (loss) $ 42 $ 22 $ 108 $ (14) Interest (income) (6) (5) (16) (18) Interest expense 12 11 39 28 Income tax expense (benefi
Indivior Pharmaceuticals — Q3 2025 Earnings Presentation on 6ix